Clinical trials: Macular Pigment
Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration
Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
Primary Objectives: To assess the efficacy of intravitreal administered Eylea in preventing visual loss in subjects with a retinal pigment epithelial detachment (PED) subtype of neovascular age-related macular degeneration (AMD)…
- Trial name
- NCT02142296
- Testing
- Eylea
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Age Macular Degeneration
Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine
The Age Macular Degeneration (AMD) is the first cause of blindness in industrialized countries. The macular pigment (lutein and zeaxanthin) could play an important role in the arisen of the AMD.
- Trial name
- MAIS (NCT02113254)
- Testing
- Corn zeaxanthin
- Where
- France
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Idiopathic Juxtafoveal Telangiectasia
The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
Macular telangiectasia type 2 ("MacTel Type 2") is an uncommon eye disorder that results in slow vision loss beginning in middle age.
- Trial name
- NCT01354093
- Testing
- zeaxanthin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Paul S. Bernstein
Pigment Epithelial Detachment
Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
- Trial name
- NCT00976222
- Testing
- intravitreal injection with ranibizumab
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Muenster
AMD - Age-Related Macular Degeneration
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular…
- Trial name
- NCT07418177
- Testing
- hiPSC-RPEs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diabetic Retinopathy, Retinal Degeneration
The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes
It has been hypothesized that thermal damage of laser pan-retinal photocoagulation may affect macular pigment as well as inner layer cells in the retina, so it was aimed to investigate possible effect of conventional laser…
- Conditions
- Diabetic Retinopathy, Retinal Degeneration, Macula Abnormality, Laser Burn of Retina
- Trial name
- NCT03150654
- Testing
- Laser pan-retinal photocoagulation
- Volunteers
- 36 people
- Sponsor
- Afyon Kocatepe University Hospital
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Age-Related Macular Degeneration
The Influence of Lutein Supplements on Age-related Macular Degeneration
Rationale: Age-related macular degeneration is the most common cause of blindness in the industrialized world. Macular pigment is hypothesized to protect against the vision loss in this disease. Objective: 1.
- Trial name
- NCT01042860
- Testing
- Lutein
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center